JPWO2021005183A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021005183A5 JPWO2021005183A5 JP2022500764A JP2022500764A JPWO2021005183A5 JP WO2021005183 A5 JPWO2021005183 A5 JP WO2021005183A5 JP 2022500764 A JP2022500764 A JP 2022500764A JP 2022500764 A JP2022500764 A JP 2022500764A JP WO2021005183 A5 JPWO2021005183 A5 JP WO2021005183A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutically
- use according
- pyrazolo
- pyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 10
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 10
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 10
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- NGNHXYCLUMQSKR-UHFFFAOYSA-N 4,6-diphenyl-2h-pyrazolo[3,4-b]pyridin-3-amine Chemical compound C12=C(N)NN=C2N=C(C=2C=CC=CC=2)C=C1C1=CC=CC=C1 NGNHXYCLUMQSKR-UHFFFAOYSA-N 0.000 claims 7
- 206010006187 Breast cancer Diseases 0.000 claims 6
- 208000026310 Breast neoplasm Diseases 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 206010060862 Prostate cancer Diseases 0.000 claims 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 6
- 230000001419 dependent effect Effects 0.000 claims 6
- 229940088597 hormone Drugs 0.000 claims 6
- 239000005556 hormone Substances 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 210000000056 organ Anatomy 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 5
- 229960004679 doxorubicin Drugs 0.000 claims 5
- 229960004671 enzalutamide Drugs 0.000 claims 5
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 5
- 239000003446 ligand Substances 0.000 claims 5
- 229960001603 tamoxifen Drugs 0.000 claims 5
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 4
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 4
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 4
- 206010033128 Ovarian cancer Diseases 0.000 claims 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 4
- 229960004316 cisplatin Drugs 0.000 claims 4
- -1 dokitaxel Chemical compound 0.000 claims 4
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 4
- 229960004891 lapatinib Drugs 0.000 claims 4
- 201000004228 ovarian endometrial cancer Diseases 0.000 claims 4
- 230000000973 chemotherapeutic effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000001024 immunotherapeutic effect Effects 0.000 claims 2
- 238000009169 immunotherapy Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- CUYKNJBYIJFRCU-UHFFFAOYSA-N 3-aminopyridine Chemical compound NC1=CC=CN=C1 CUYKNJBYIJFRCU-UHFFFAOYSA-N 0.000 claims 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201930643 | 2019-07-10 | ||
| ESP201930643 | 2019-07-10 | ||
| PCT/EP2020/069459 WO2021005183A1 (en) | 2019-07-10 | 2020-07-09 | Inhibitor of map kinase interacting serine/threonine kinase 1 (mnk1) and map kinase interacting serine/threonine kinase 2 (mnk2), cancer therapy and therapeutic combinations |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022539840A JP2022539840A (ja) | 2022-09-13 |
| JPWO2021005183A5 true JPWO2021005183A5 (https=) | 2023-07-18 |
| JP2022539840A5 JP2022539840A5 (https=) | 2023-07-18 |
| JP7536243B2 JP7536243B2 (ja) | 2024-08-20 |
Family
ID=71607975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022500764A Active JP7536243B2 (ja) | 2019-07-10 | 2020-07-09 | Ｍａｐキナーゼ相互作用セリン／スレオニン－プロテインキナーゼ１（ｍｎｋ１）及びｍａｐキナーゼ相互作用セリン／スレオニン－プロテインキナーゼ２（ｍｎｋ２）の阻害剤、癌治療及び治療的組合せ |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220257571A1 (https=) |
| EP (1) | EP3996710B1 (https=) |
| JP (1) | JP7536243B2 (https=) |
| ES (1) | ES3014017T3 (https=) |
| WO (1) | WO2021005183A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11958832B1 (en) | 2023-10-12 | 2024-04-16 | King Faisal University | 2-alkoxy[4,3:6,3-terpyridine]-3-carbonitriles as antimicrobial compounds |
| US11926611B1 (en) | 2023-11-24 | 2024-03-12 | King Faisal University | 2-(2-ethoxyethoxy)-6-phenyl-4,4′-bipyridine-3-carbonitrile as an antimicrobial compound |
| US12071407B1 (en) | 2023-12-05 | 2024-08-27 | King Faisal University | 6-(4-hydroxyphenyl)-2-(2-ethoxyethoxy)-4-(4-methoxyphenyl)nicotinonitrile as an antimicrobial compound |
| US11970451B1 (en) | 2023-12-07 | 2024-04-30 | King Faisal University | 6-(3-hydroxyphenyl)-2-methoxy-4-(3-methylphenyl)nicotinonitrile as an antimicrobial compound |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2160780A1 (de) | 1971-12-08 | 1973-06-14 | Basf Ag | Pyridino-pyrazole |
| US20100113415A1 (en) * | 2008-05-29 | 2010-05-06 | Rajapakse Hemaka A | Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer |
| EP2464647B1 (en) | 2009-08-11 | 2016-09-21 | Bristol-Myers Squibb Company | Azaindazoles as btk kinase modulators and use thereof |
| AU2014289415A1 (en) | 2013-07-08 | 2016-01-21 | Bayer Pharma Aktiengesellschaft | Substituted pyrazolo-pyridinamines |
| US10702526B2 (en) * | 2015-04-20 | 2020-07-07 | Effector Therapeutics Inc. | Inhibitors of immune checkpoint modulators and related methods |
-
2020
- 2020-07-09 ES ES20739952T patent/ES3014017T3/es active Active
- 2020-07-09 JP JP2022500764A patent/JP7536243B2/ja active Active
- 2020-07-09 US US17/625,075 patent/US20220257571A1/en not_active Abandoned
- 2020-07-09 WO PCT/EP2020/069459 patent/WO2021005183A1/en not_active Ceased
- 2020-07-09 EP EP20739952.8A patent/EP3996710B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Brown et al. | Cisplatin-based chemotherapy of human cancers | |
| JP6404242B2 (ja) | がんの治療のための併用療法としてのエリブリンおよびレンバチニブの使用 | |
| CN113768933B (zh) | Parp抑制剂用于治疗化疗耐药的卵巢癌或乳腺癌的用途 | |
| ES2870805T3 (es) | Tratamiento combinado de cáncer | |
| ES2941894T3 (es) | Régimen de tratamiento que utiliza neratinib contra el cáncer de mama | |
| CN101669941B (zh) | 一种联合用药治疗恶性肿瘤的方法以及抗恶性肿瘤的药物 | |
| CN111727059A (zh) | 包含至少一种剪接体调控剂和至少一种选自BCL2抑制剂、BCL2/BCLxL抑制剂和BCLxL抑制剂的抑制剂的组合及其使用方法 | |
| JP2021523189A (ja) | ビスフルオロアルキル−１，４−ベンゾジアゼピノン化合物を含む組成物およびその使用方法 | |
| JPWO2021005183A5 (https=) | ||
| JP2024125140A5 (https=) | ||
| JP2021511344A5 (https=) | ||
| CN102688493B (zh) | 含有白藜芦醇及白藜芦醇类衍生物和Bc1-2抑制剂的药物组合物及其应用 | |
| WO2020236668A1 (en) | Leukadherin-1 alone or in combination for use in the treatment of cancer | |
| TW202110448A (zh) | Ｐａｒｐ抑制劑聯合ｖｅｇｆｒ抑制劑用於治療卵巢癌或乳腺癌的用途 | |
| JP2021518348A5 (https=) | ||
| Chi et al. | Advanced ovarian cancer | |
| JP2006523664A5 (https=) | ||
| JP7311177B2 (ja) | Ａ－ＮＯＲ－５αアンドロスタン薬物と抗がん薬物との併用 | |
| JP2021501160A (ja) | 血液がんおよび固形がんの処置のためのカルシウム放出活性化カルシウムチャネルモジュレーター | |
| TWI912688B (zh) | 用於治療三陰性乳癌之藥物組合物 | |
| CN119950745B (zh) | 一种药物组合物及其在制备抗肿瘤药物中的应用 | |
| JPWO2019144098A5 (https=) | ||
| US20250241923A1 (en) | A dual selective pi3k delta and gamma inhibitors and/or a salt-inducible kinase 3 inhibitor for treating solid tumors | |
| JP2016521760A (ja) | がんの処置のための、ｒｏ５５０３７８１、カペシタビン及びオキサリプラチンの組み合わせ | |
| RU2777519C2 (ru) | Применение ингибитора parp в лечении резистентного к химиотерапии рака яичников или рака молочной железы |